PHARMACEUTICAL%20REGULATORY%20AND%20COMPLIANCE%20CONGRESS%20AND%20BEST%20PRACTICES%20FORUM%20Privacy%20Regulation%20of%20the%20Pharmaceutical%20Sector

1
PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS
AND BEST PRACTICES FORUM Privacy Regulation of
the Pharmaceutical Sector

• 14 November 2003
• Washington, DC
• Joan Antokol, Chief Privacy Officer Oliver
  Johnson, II, Chief Privacy Officer
• Novartis Pharmaceuticals Corporation Merck Co.,
  Inc.
• John Clay, Senior Advisor, E-Business Jonathan
  Smollen, Chief Privacy Officer
• North American Commercial Operations Wyeth
  Pharmaceuticals
• Aventis Pharmaceuticals
• MODERATOR
• Stanley Crosley, Chief Privacy Officer
• Eli Lilly and Company

2
GLOBAL PRIVACY CONSIDERATIONS FOR
PHARMACEUTICALCOMPANIES
Sales
Research
(e.g, relationship with physicians, Patient
Assistance Programs, prescriber data,
preceptorships)
(e.g., pharmacovigilance, subject recruitment,
subject enrollment)
Pharmaceutical Company
Marketing
Human Resources
(customer relations management, e.g, call
centers, web sites, coupons, business reply cards)
(e.g, benefit plans, corporate health (on-site
clinics), employee data)
Other
(e.g., stockholder services, investor relations)
3
Overview

• I. Introductions
• II. Overview of Panel Discussion
• III. Panel Discussion
• Business Case for Privacy Compliance
• Practical Compliance Considerations
• IV. Questions Answers